Varsha Bandil, Jeetendra Kumar Gupta, Manoj Goyal
Varsha Bandil1*, Jeetendra Kumar Gupta1, Manoj Goyal2
1Institute of Pharmaceutical Research, GLA University, Mathura, U.P. 281406, India.
2Jai Institute of Pharmaceutical Sciences and Research, Vism Campus, Gwalior, M.P. 474001, India.
Volume - 14,
Issue - 3,
Year - 2021
Vinorelbine is a semi synthetic vinca organic compound that has been exposed dynamic in numerous tumor types and is right now enrolled for the cure of advanced breast cancer (ABC) and non-small cell lung cancer (NSCLC). Evaluation of its pharmacokinetic and toxic outline and give understanding into its future as a NSCLC and ABC remedial. Its marketed formulation has been accounted for to have serious aspect effects, like venous irritation and phlebitis proximal to the site of infusions, likewise restricted rashes and urticaria. Our long run aim in synthesizing a novel nanomicellar vinorelbine formulation is to decrease or perhaps eliminate these adverse effect and increment medicate action by formulating the medication in a lipid-based framework as a nanomedicine focused to the location of activity.
Cite this article:
Varsha Bandil, Jeetendra Kumar Gupta, Manoj Goyal. Vinorelbine: A Potential Breakthrough in Cancer Therapy. Research J. Pharm. and Tech 2021; 14(3):1823-1827. doi: 10.5958/0974-360X.2021.00323.1
1. Johnson SAN. Vinorelbine: an update and review of activity. Clin. Oncology. 1996; 8: 353.
2. Brunello A, Rome A, Basso U and Jirillo A. A review of vinorelbine in the treatment of advanced breast cancer. Clin. Med.: Therapeutics. 2009; 1: 1716.
3. Gregory RK and Smith IE. Vinorelbine-a clinical review. Br. J. Cancer. 2000; 82(12): 1907, 1908.
4. Drug bank, Vinorelbine: https://www.drugbank.ca/drugs/ DB00361.
5. Breast Cancer Now, the research and care charity: https:// breastcancernow.org/information-support/facing-breast-cancer/ going-through-treatment-breast-cancer/chemotherapy/ vinorelbine-navelbine.
6. Cancer Treatment Centers of America: https:// www.cancercenter.com/cancer-types/breast-cancer/types/rare-breast-cancer-types/metastatic-breast-cancer.
7. Herbst RS, Morgensztern D and Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018; 553: 446.
8. Duma N, Davila RS and Molina JR. Non-small cell lung cancer: epidemiology screening, diagnosis and treatment. Mayo Clin. Proceedings. 2019; 94(8): 1624-1625.
9. Pierre Fabre Medicament. Internal report. 1993; 259(2): 36.
10. National Cancer Institute: https://ncit.nci.nih.gov/ncitbrowser/ ConceptReport.jsp?dictionary=NCI_Thesaurusandns=NCI_Thesaurusandcode=C1275.
11. Chun R, Garrett LD and Vail DM. Cancer Chemotherapy. Withrow and Macewen’s Small Animal Clinical Oncology, Edited by Wthrow SJ and Vail DM. 2007; 4th ed: pp.166.
12. Wang LG, Liu XM, Kreis W and Budman DR. The effect of antimicrotubule agent on signal transduction pathway of apoptosis: a review. Cancer Chemother. Pharmacology. 1999; 44: 355-361.
13. Wang LG, Xiu XM and Chao DL. Activation of MAP kinase by vinorelbine in MCF-7 cells. Proc. Am. Assoc. Cancer Res. 1999; 40: 13.
14. National Library of Medicine: https://pubchem.ncbi.nlm.nih.gov/ compound/Vinorelbine#section=Absorption-Distribution-and-Excretion
15. Caffo O, Dipasquale M, Murgia V, Veccia A and Galligioni E. An evaluation of the pharmacokinetics and clinical use of vinorelbine for NSCLC treatment. Expert Opinion on Drug Metabolism and Toxicology. 2013; 9(8): 1039.
16. Goa KL and Faulds D. Vinorelbine: a review of its pharmacological properties and clinical use in cancer chemotherapy. Drug and Aging. 1994; 5(3): 209.
17. Krikorian A and Breillont F. Vinorelbine (Navelbine). a new semisynthetic vinca alkaloid. Oncol. Res. And Treatment. 1991; 14(1): 8-10.
18. Bahadori F, Topcu G, Eroglu MS and Onyuksel H. A new lipid-based nano formulation of vinorelbine. AAPS Pharm SciTech. 2014; 15(5): 1147.
19. Morimoto Y, Miyawaki K, Seki R, Watanabe K, Hirohara M and Shinohara T. Risk factors of venous irritation in patients receiving vinorelbine: a retrospective study. J. of Pharm. Health Care and Sci. 2018; 4(1): 1.